NZ187908A - Pharmaceutical, veterinary, and dietary formulations containing (all-z)-5,8,11,14,17-eicosapentaenoic acid - Google Patents

Pharmaceutical, veterinary, and dietary formulations containing (all-z)-5,8,11,14,17-eicosapentaenoic acid

Info

Publication number
NZ187908A
NZ187908A NZ187908A NZ18790878A NZ187908A NZ 187908 A NZ187908 A NZ 187908A NZ 187908 A NZ187908 A NZ 187908A NZ 18790878 A NZ18790878 A NZ 18790878A NZ 187908 A NZ187908 A NZ 187908A
Authority
NZ
New Zealand
Prior art keywords
formulation
eicosapentaenoic acid
formulation according
pharmaceutically acceptable
ester
Prior art date
Application number
NZ187908A
Other languages
English (en)
Inventor
H O Bang
J Dyerberg
S E Moncada
J R Vane
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB2357578A external-priority patent/GB1604554A/en
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of NZ187908A publication Critical patent/NZ187908A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C15/00—Butter; Butter preparations; Making thereof
    • A23C15/12—Butter preparations
    • A23C15/126—Butter containing a minority of vegetable oils; Enrichment of butter with fatty acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings or cooking oils
    • A23D9/007—Other edible oils or fats, e.g. shortenings or cooking oils characterised by ingredients other than fatty acid triglycerides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings or cooking oils
    • A23D9/007—Other edible oils or fats, e.g. shortenings or cooking oils characterised by ingredients other than fatty acid triglycerides
    • A23D9/013—Other fatty acid esters, e.g. phosphatides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NZ187908A 1978-05-26 1978-07-19 Pharmaceutical, veterinary, and dietary formulations containing (all-z)-5,8,11,14,17-eicosapentaenoic acid NZ187908A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB2357478 1978-05-26
GB2357578A GB1604554A (en) 1978-05-26 1978-05-26 Pharmaceutical and food formulations

Publications (1)

Publication Number Publication Date
NZ187908A true NZ187908A (en) 1984-05-31

Family

ID=26256599

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ187908A NZ187908A (en) 1978-05-26 1978-07-19 Pharmaceutical, veterinary, and dietary formulations containing (all-z)-5,8,11,14,17-eicosapentaenoic acid

Country Status (13)

Country Link
JP (1) JPS5515444A (enExample)
AU (1) AU527784B2 (enExample)
CA (1) CA1151068A (enExample)
CH (1) CH644267A5 (enExample)
DE (1) DE2831507A1 (enExample)
ES (1) ES8104983A1 (enExample)
FR (1) FR2426461A1 (enExample)
IE (1) IE48287B1 (enExample)
IL (1) IL55227A (enExample)
IT (1) IT1116505B (enExample)
NL (1) NL191332C (enExample)
NZ (1) NZ187908A (enExample)
SE (1) SE448678B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922345A (en) * 1990-12-07 1999-07-13 Scotia Holdings Plc Nutrition

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5735512A (en) * 1980-06-27 1982-02-26 Nippon Oil & Fats Co Ltd Preventive and remedy for thrombosis
JPS59172416A (ja) * 1983-03-18 1984-09-29 Terumo Corp 脂肪輸液
FR2548021B1 (fr) * 1983-06-29 1986-02-28 Dick P R Compositions pharmaceutiques dermiques a action prolongee et continue a base d'acides gras essentiels
CA1239587A (en) * 1983-10-24 1988-07-26 David Rubin Combined fatty acid composition for lowering blood cholestrol and triglyceride levels
JPS60132916A (ja) * 1983-12-21 1985-07-16 Nisshin Oil Mills Ltd:The 血栓症予防食品または医薬品
US4752618A (en) * 1984-07-12 1988-06-21 New England Deaconess Hospital Method of minimizing efects of infection through diet
JPH0748991B2 (ja) * 1984-08-29 1995-05-31 日本油脂株式会社 経管栄養組成物
GB8710780D0 (en) * 1987-05-07 1987-06-10 Scras Opthalmological application of eicosapentaenoic acid
GB8819110D0 (en) * 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
WO1993020717A2 (en) * 1992-04-13 1993-10-28 Research Corporation Technologies, Inc. Reducing gastrointestinal irritation in infant nutrition
NL9401743A (nl) * 1994-10-20 1996-06-03 Prospa Bv Zouten van aminoalcoholen en farmaceutische formuleringen die deze bevatten.
DE19503993A1 (de) * 1995-02-08 1996-08-14 Johann Friedrich Dr Med Desaga Verwendung eines Produktes zur enteralen Versorgung mit Lebensmittelinhaltsstoffen oder Arzneimittelinhaltsstoffen
DE10056351A1 (de) * 2000-11-14 2002-05-29 Weylandt Karsten Henrich Pharmazeutisches Präparat
GB0403247D0 (en) 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
CN107233337A (zh) 2009-04-29 2017-10-10 阿马里纳药物爱尔兰有限公司 含有epa和心血管剂的药物组合物以及使用其的方法
MX377553B (es) 2009-04-29 2025-03-10 Amarin Pharma Inc Composicion farmaceutica estable y metodos de uso de la misma.
BRPI1011883A2 (pt) 2009-06-15 2016-09-13 Amarin Pharma Inc uso de composições para redução de triglicerídeos sem elevar os níveis de o ldl-c em um paciente sob o tratamento concomitante com estatina
NZ599061A (en) 2009-09-23 2014-05-30 Amarin Pharmaceuticals Ie Ltd Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
WO2013070735A1 (en) 2011-11-07 2013-05-16 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2800469B1 (en) 2012-01-06 2021-08-25 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
US9603826B2 (en) 2012-06-29 2017-03-28 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
SG10201706205RA (en) 2013-02-06 2017-08-30 Agency Science Tech & Res Methods for reducing aggregate levels in protein preparations by treatment with thio-heterocyclic cations
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10966951B2 (en) 2017-05-19 2021-04-06 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
MA50490A (fr) 2018-09-24 2020-09-02 Amarin Pharmaceuticals Ie Ltd Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
CA3160676A1 (en) 2019-11-12 2021-05-20 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE319677B (enExample) * 1965-03-27 1970-01-19 Sumitomo Chemical Co
FR2097036A1 (en) * 1970-07-29 1972-03-03 Sopharga Lab Lipids contg fatty acids - for treatment of atheroslerosis
GB1476624A (en) * 1973-05-30 1977-06-16 Cepbepe Tranquiliser medicaments
GB1580444A (en) * 1976-11-04 1980-12-03 Bio Oil Res Pharmaceutical compositions
JPS6257605A (ja) * 1985-09-05 1987-03-13 Kaizuka Kazutoshi 多元素鉱物からの有効成分抽出方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922345A (en) * 1990-12-07 1999-07-13 Scotia Holdings Plc Nutrition

Also Published As

Publication number Publication date
FR2426461B1 (enExample) 1983-02-11
SE448678B (sv) 1987-03-16
ES480921A0 (es) 1981-05-16
IE791023L (en) 1979-11-26
JPS5515444A (en) 1980-02-02
ES8104983A1 (es) 1981-05-16
NL191332C (nl) 1995-06-01
DE2831507A1 (de) 1979-11-29
CA1151068A (en) 1983-08-02
IE48287B1 (en) 1984-11-28
SE7904570L (sv) 1979-11-27
NL191332B (nl) 1995-01-02
NL7904144A (nl) 1979-11-28
IT1116505B (it) 1986-02-10
CH644267A5 (en) 1984-07-31
DE2831507C2 (enExample) 1989-07-13
AU527784B2 (en) 1983-03-24
IT7947717A0 (it) 1979-01-19
IL55227A (en) 1982-12-31
IL55227A0 (en) 1978-09-29
AU3808478A (en) 1980-01-17
FR2426461A1 (fr) 1979-12-21

Similar Documents

Publication Publication Date Title
IE48287B1 (en) Fatty acid and derivatives thereof for use in treatment of prophylaxis of thrombo-embolic conditions
GB2033745A (en) Fatty acid and derivatives thereof in treatment or prophylaxis of thrombo-embolic conditions
Sanders et al. The influence of different types of ω 3 polyunsaturated fatty acids on blood lipids and platelet function in healthy volunteers
JP2662728B2 (ja) オメガ―３脂肪酸エステルの速効性静脈内エマルジョン
CA1280370C (en) PHARMACEUTICAL AND DIETARY COMPOSITION CONTAINING .alpha.-LINOLEIC ACID
Connor The beneficial effects of omega-3 fatty acids: cardiovascular disease and neurodevelopment
EP0321128B1 (en) Fatty acid compositions
US4820731A (en) Parenteral dietary supplement and method of minimizing effects of infection through diet
Mehta et al. Dietary supplementation with omega-3 polyunsaturated fatty acids in patients with stable coronary heart disease: effects on indices of platelet and neutrophil function and exercise performance
JP5827784B2 (ja) ビタミンｋ２を含む医薬及び栄養補助製品
US4058594A (en) Immuno-suppressive agents
Friedman et al. Essential fatty acids and the major urinary metabolites of the E prostaglandins in thriving neonates and in infants receiving parenteral fat emulsions
JPH08500332A (ja) 炎症性疾患の治療のための非経口的に投与される医薬を調製するためのエマルジョンの使用
GB1604554A (en) Pharmaceutical and food formulations
US3993775A (en) Immuno-suppressive agents
GB2148713A (en) Pharmaceutical composition and food product comprising higher fatty acids
GB1580444A (en) Pharmaceutical compositions
JPS6257605B2 (enExample)
EP0201159A2 (en) Pharmaceutical and dietary compositions containing linolenic acids for the treatment of benign prostatic hypertrophy
Sanders Influence of fish-oil supplements on man
US9808437B2 (en) Monounsaturated fatty acid compositions and use for treating atherosclerosis
US4097602A (en) Method of inhibiting blood platelet aggregation
Kinsella et al. Prostaglandins and their precursors in tissues from rats fed on trans, trans-linoleate
JP3664814B2 (ja) 血中脂質改善剤及び食品添加剤
PT87017B (pt) Processo para a preparacao de composicoes farmaceuticas que actuam sobre o coracao e o sistema cardiovascular contendo uma mistura de algas com selenio com acidos gordos insaturados superiores